Multiple Sclerosis Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have been diagnosed with multiple sclerosis.
- People who have been given a CD20-targeting medication (such as rituximab, ocrelizumab, or ofatumumab) within 6 to 12 months before or during pregnancy.
- People who have been given another type of immune-modifying medication within 6 to 12 months before or during pregnancy.
- People who have not received any multiple sclerosis treatment within 6 to 12 months before or during pregnancy.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have previously had a stem cell transplant.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Katharina Fink, MD, Dr. med., Karolinska Institutet
Phone: +46706571789
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Effect on infant immune system; Effect on infant immune system; Effect on infant immune system; Effect on infant immune system
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.